Skip to main content
SCI logo

SCI — Investor Relations & Filings

Ticker · 4119 ISIN · TW0004119003 TW Manufacturing
Open in API
Filings indexed 1,697 across all filing types
Latest filing 2018-12-07 Regulatory Filings
Country TW Taiwan
Listing TW 4119

About SCI

www.sci-pharmtech.com.tw

SCI Pharmtech, Inc. specializes in the research, development, manufacturing, and marketing of Active Pharmaceutical Ingredients (APIs), pharmaceutical intermediates, and specialty chemicals. Established in 1987 and originally founded by the Swiss Siegfried Group, the company provides high-quality chemical solutions and custom manufacturing services to leading global pharmaceutical corporations across Europe, North America, and Japan. Its core operations encompass advanced chemical synthesis, process optimization, and large-scale production within GMP-compliant facilities. With a robust R&D infrastructure including specialized laboratories and pilot plants, the company delivers technical excellence in complex chemical processing. SCI Pharmtech maintains a strong focus on quality assurance and international regulatory compliance, positioning itself as a reliable partner for the global healthcare and life sciences sectors.

Recent filings

Filing Released Lang Actions
107年11月營業收入
Regulatory Filings Classification · 85% confidence The document is a revenue summary report for a specific month and year (民國107年11月, which corresponds to November 2018) provided by a listed company. It contains numerical data on net operating revenue for the month and year-to-date, with comparisons to the previous year and explanations for changes. The document is short (820 characters) and primarily presents financial data for a short period, but it does not contain comprehensive financial statements or detailed analysis typical of an Interim/Quarterly Report (IR). It is more of a regulatory revenue disclosure or summary report. Given the nature and length, and that it is a regulatory disclosure of financial data without full financial statements, it best fits under Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements and compliance documents that do not fit other categories.
2018-12-07 Chinese
107年第3季海外子公司投資
Interim / Quarterly Report Classification · 90% confidence The document contains financial data related to investment in overseas subsidiaries, including investment amounts, holding percentages, and recognized investment gains or losses for a specific period (107th year, 3rd quarter). The content is tabular and provides detailed financial figures, indicating it is a substantive financial report rather than a brief announcement or certification. The presence of quarterly period data and detailed investment accounting aligns with an Interim / Quarterly Report (IR). The document length is short but contains actual financial data, so it is not a report publication announcement or regulatory filing. Therefore, the best classification is Interim / Quarterly Report (IR). 9M 2018
2018-11-14 Chinese
107年第3季財務報告書 — 201804_4119_AI3.pdf
Regulatory Filings
2018-11-13 Chinese
107年第3季財務報告書 — 201804_4119_AI1.pdf
Regulatory Filings
2018-11-13 Chinese
107年第3季財務報告書 — 201803_4119_AI1.pdf
Regulatory Filings
2018-11-13 Chinese
107年第3季財務報告書 — 201802_4119_AI1.pdf
Regulatory Filings
2018-11-13 Chinese

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.